Stocktoria
Spyre Therapeutics, Inc. SYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-04-07
Spyre Therapeutics, Inc. statistics & valuation
Market cap$7.6B
P / B10.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -27348.0% | -3640.2% | -350.3% |
| Net margin | — | — | -38238.1% | -3598.8% | -351.1% |
| FCF margin | — | — | -11276.5% | -3442.8% | -289.7% |
| Return on assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% |
| Return on equity | -21.7% | -40.2% | -184.1% | -166.6% | -78.4% |
| Current ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 |
| Revenue growth | — | -100.0% | -62.0% | -87.6% | — |
Source: SEC EDGAR filings · CIK 0001636282 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.